The global Hemophilia Drugs market was valued at US$ 13100 million in 2022 and is projected to reach US$ 17160 million by 2029, at a CAGR of 3.9% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The hemophilia treatment drugs market is experiencing entry of a large number of new drugs in the market. Few of them have already arrived and other long lasting clotting factors and more promising drugs are on their way to get launched in this market. For instance, follow up data from phase I/II study of hemophilia medicine ?Emicizumab? by Roche has demonstrated promising results regarding safety and prophylactic efficiency in people with severe hemophilia A. Another example is of ?Eloctate? for type A and ?Aprolix? for type B hemophilia, respectively. These two newly arrived biogen products are opposed to commonly prescribe course of three infusions per week as they are longer-acting than traditional treatments and require only one to two infusions per week, due to their new mechanism of action.
This report aims to provide a comprehensive presentation of the global market for Hemophilia Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hemophilia Drugs. This report contains market size and forecasts of Hemophilia Drugs in global, including the following market information:
- Global Hemophilia Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
- Global Hemophilia Drugs Market Sales, 2018-2023, 2024-2029, (K Units)
- Global top five Hemophilia Drugs companies in 2022 (%)
With increasing attention on prophylactic treatment, the market for hemophilia drugs is estimated to have a positive outlook over the coming years. The prophylactic treatment approach prevents spontaneous bleeding episodes, significantly improves the quality of life in terms of physical activities, and maintains the level of clotting factors above a baseline. According to the studies conducted by the US National Library of Medicine determined that the savings on prophylactic treatment be approximately USD 8,312 to USD 17,675 per bleeding episode in a person. Moreover, this line of treatment reduces joint damage and suffering from pain. Several of such long-acting therapeutics are under development and expected to be launched over the next four years. The shift in preference for prophylactic treatment due to its advantages will drive this market?s growth over the forecast period.
We surveyed the Hemophilia Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Hemophilia Drugs Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Hemophilia Drugs Market Segment Percentages, by Type, 2022 (%)
- Hemophilia A
- Inhibitors
- Hemophilia B
- Von Willebrand Disease
Global Hemophilia Drugs Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Hemophilia Drugs Market Segment Percentages, by Application, 2022 (%)
- Recombinant Therapies
- Plasma-Derived Therapies
Global Hemophilia Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Hemophilia Drugs Market Segment Percentages, By Region and Country, 2022 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Hemophilia Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Hemophilia Drugs revenues share in global market, 2022 (%)
Key companies Hemophilia Drugs sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Hemophilia Drugs sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Baxalta
- Bayer
- CSL Behring
- Pfizer
- Alnylam Pharmaceuticals
- BioMarin
- Catalyst Biosciences
- Dimension Therapeutics
- F. Hoffmann-La Roche
- Grifols
- Octapharma
- Sangamo Biosciences
- Spark Therapeutics
- Swedish Orphan Biovitrum
Outline of Major Chapters:
- Chapter 1: Introduces the definition of Hemophilia Drugs, market overview.
- Chapter 2: Global Hemophilia Drugs market size in revenue and volume.
- Chapter 3: Detailed analysis of Hemophilia Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
- Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
- Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
- Chapter 6: Sales of Hemophilia Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
- Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
- Chapter 8: Global Hemophilia Drugs capacity by region & country.
- Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
- Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
- Chapter 11: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Hemophilia Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Hemophilia Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Hemophilia Drugs Overall Market Size
2.1 Global Hemophilia Drugs Market Size: 2022 VS 2029
2.2 Global Hemophilia Drugs Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Hemophilia Drugs Sales: 2018-2029
3 Company Landscape
3.1 Top Hemophilia Drugs Players in Global Market
3.2 Top Global Hemophilia Drugs Companies Ranked by Revenue
3.3 Global Hemophilia Drugs Revenue by Companies
3.4 Global Hemophilia Drugs Sales by Companies
3.5 Global Hemophilia Drugs Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Hemophilia Drugs Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Hemophilia Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Hemophilia Drugs Players in Global Market
3.8.1 List of Global Tier 1 Hemophilia Drugs Companies
3.8.2 List of Global Tier 2 and Tier 3 Hemophilia Drugs Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Hemophilia Drugs Market Size Markets, 2022 & 2029
4.1.2 Hemophilia A
4.1.3 Inhibitors
4.1.4 Hemophilia B
4.1.5 Von Willebrand Disease
4.2 By Type - Global Hemophilia Drugs Revenue & Forecasts
4.2.1 By Type - Global Hemophilia Drugs Revenue, 2018-2023
4.2.2 By Type - Global Hemophilia Drugs Revenue, 2024-2029
4.2.3 By Type - Global Hemophilia Drugs Revenue Market Share, 2018-2029
4.3 By Type - Global Hemophilia Drugs Sales & Forecasts
4.3.1 By Type - Global Hemophilia Drugs Sales, 2018-2023
4.3.2 By Type - Global Hemophilia Drugs Sales, 2024-2029
4.3.3 By Type - Global Hemophilia Drugs Sales Market Share, 2018-2029
4.4 By Type - Global Hemophilia Drugs Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Hemophilia Drugs Market Size, 2022 & 2029
5.1.2 Recombinant Therapies
5.1.3 Plasma-Derived Therapies
5.2 By Application - Global Hemophilia Drugs Revenue & Forecasts
5.2.1 By Application - Global Hemophilia Drugs Revenue, 2018-2023
5.2.2 By Application - Global Hemophilia Drugs Revenue, 2024-2029
5.2.3 By Application - Global Hemophilia Drugs Revenue Market Share, 2018-2029
5.3 By Application - Global Hemophilia Drugs Sales & Forecasts
5.3.1 By Application - Global Hemophilia Drugs Sales, 2018-2023
5.3.2 By Application - Global Hemophilia Drugs Sales, 2024-2029
5.3.3 By Application - Global Hemophilia Drugs Sales Market Share, 2018-2029
5.4 By Application - Global Hemophilia Drugs Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region - Global Hemophilia Drugs Market Size, 2022 & 2029
6.2 By Region - Global Hemophilia Drugs Revenue & Forecasts
6.2.1 By Region - Global Hemophilia Drugs Revenue, 2018-2023
6.2.2 By Region - Global Hemophilia Drugs Revenue, 2024-2029
6.2.3 By Region - Global Hemophilia Drugs Revenue Market Share, 2018-2029
6.3 By Region - Global Hemophilia Drugs Sales & Forecasts
6.3.1 By Region - Global Hemophilia Drugs Sales, 2018-2023
6.3.2 By Region - Global Hemophilia Drugs Sales, 2024-2029
6.3.3 By Region - Global Hemophilia Drugs Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country - North America Hemophilia Drugs Revenue, 2018-2029
6.4.2 By Country - North America Hemophilia Drugs Sales, 2018-2029
6.4.3 US Hemophilia Drugs Market Size, 2018-2029
6.4.4 Canada Hemophilia Drugs Market Size, 2018-2029
6.4.5 Mexico Hemophilia Drugs Market Size, 2018-2029
6.5 Europe
6.5.1 By Country - Europe Hemophilia Drugs Revenue, 2018-2029
6.5.2 By Country - Europe Hemophilia Drugs Sales, 2018-2029
6.5.3 Germany Hemophilia Drugs Market Size, 2018-2029
6.5.4 France Hemophilia Drugs Market Size, 2018-2029
6.5.5 U.K. Hemophilia Drugs Market Size, 2018-2029
6.5.6 Italy Hemophilia Drugs Market Size, 2018-2029
6.5.7 Russia Hemophilia Drugs Market Size, 2018-2029
6.5.8 Nordic Countries Hemophilia Drugs Market Size, 2018-2029
6.5.9 Benelux Hemophilia Drugs Market Size, 2018-2029
6.6 Asia
6.6.1 By Region - Asia Hemophilia Drugs Revenue, 2018-2029
6.6.2 By Region - Asia Hemophilia Drugs Sales, 2018-2029
6.6.3 China Hemophilia Drugs Market Size, 2018-2029
6.6.4 Japan Hemophilia Drugs Market Size, 2018-2029
6.6.5 South Korea Hemophilia Drugs Market Size, 2018-2029
6.6.6 Southeast Asia Hemophilia Drugs Market Size, 2018-2029
6.6.7 India Hemophilia Drugs Market Size, 2018-2029
6.7 South America
6.7.1 By Country - South America Hemophilia Drugs Revenue, 2018-2029
6.7.2 By Country - South America Hemophilia Drugs Sales, 2018-2029
6.7.3 Brazil Hemophilia Drugs Market Size, 2018-2029
6.7.4 Argentina Hemophilia Drugs Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Hemophilia Drugs Revenue, 2018-2029
6.8.2 By Country - Middle East & Africa Hemophilia Drugs Sales, 2018-2029
6.8.3 Turkey Hemophilia Drugs Market Size, 2018-2029
6.8.4 Israel Hemophilia Drugs Market Size, 2018-2029
6.8.5 Saudi Arabia Hemophilia Drugs Market Size, 2018-2029
6.8.6 UAE Hemophilia Drugs Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Baxalta
7.1.1 Baxalta Company Summary
7.1.2 Baxalta Business Overview
7.1.3 Baxalta Hemophilia Drugs Major Product Offerings
7.1.4 Baxalta Hemophilia Drugs Sales and Revenue in Global (2018-2023)
7.1.5 Baxalta Key News & Latest Developments
7.2 Bayer
7.2.1 Bayer Company Summary
7.2.2 Bayer Business Overview
7.2.3 Bayer Hemophilia Drugs Major Product Offerings
7.2.4 Bayer Hemophilia Drugs Sales and Revenue in Global (2018-2023)
7.2.5 Bayer Key News & Latest Developments
7.3 CSL Behring
7.3.1 CSL Behring Company Summary
7.3.2 CSL Behring Business Overview
7.3.3 CSL Behring Hemophilia Drugs Major Product Offerings
7.3.4 CSL Behring Hemophilia Drugs Sales and Revenue in Global (2018-2023)
7.3.5 CSL Behring Key News & Latest Developments
7.4 Pfizer
7.4.1 Pfizer Company Summary
7.4.2 Pfizer Business Overview
7.4.3 Pfizer Hemophilia Drugs Major Product Offerings
7.4.4 Pfizer Hemophilia Drugs Sales and Revenue in Global (2018-2023)
7.4.5 Pfizer Key News & Latest Developments
7.5 Alnylam Pharmaceuticals
7.5.1 Alnylam Pharmaceuticals Company Summary
7.5.2 Alnylam Pharmaceuticals Business Overview
7.5.3 Alnylam Pharmaceuticals Hemophilia Drugs Major Product Offerings
7.5.4 Alnylam Pharmaceuticals Hemophilia Drugs Sales and Revenue in Global (2018-2023)
7.5.5 Alnylam Pharmaceuticals Key News & Latest Developments
7.6 BioMarin
7.6.1 BioMarin Company Summary
7.6.2 BioMarin Business Overview
7.6.3 BioMarin Hemophilia Drugs Major Product Offerings
7.6.4 BioMarin Hemophilia Drugs Sales and Revenue in Global (2018-2023)
7.6.5 BioMarin Key News & Latest Developments
7.7 Catalyst Biosciences
7.7.1 Catalyst Biosciences Company Summary
7.7.2 Catalyst Biosciences Business Overview
7.7.3 Catalyst Biosciences Hemophilia Drugs Major Product Offerings
7.7.4 Catalyst Biosciences Hemophilia Drugs Sales and Revenue in Global (2018-2023)
7.7.5 Catalyst Biosciences Key News & Latest Developments
7.8 Dimension Therapeutics
7.8.1 Dimension Therapeutics Company Summary
7.8.2 Dimension Therapeutics Business Overview
7.8.3 Dimension Therapeutics Hemophilia Drugs Major Product Offerings
7.8.4 Dimension Therapeutics Hemophilia Drugs Sales and Revenue in Global (2018-2023)
7.8.5 Dimension Therapeutics Key News & Latest Developments
7.9 F. Hoffmann-La Roche
7.9.1 F. Hoffmann-La Roche Company Summary
7.9.2 F. Hoffmann-La Roche Business Overview
7.9.3 F. Hoffmann-La Roche Hemophilia Drugs Major Product Offerings
7.9.4 F. Hoffmann-La Roche Hemophilia Drugs Sales and Revenue in Global (2018-2023)
7.9.5 F. Hoffmann-La Roche Key News & Latest Developments
7.10 Grifols
7.10.1 Grifols Company Summary
7.10.2 Grifols Business Overview
7.10.3 Grifols Hemophilia Drugs Major Product Offerings
7.10.4 Grifols Hemophilia Drugs Sales and Revenue in Global (2018-2023)
7.10.5 Grifols Key News & Latest Developments
7.11 Octapharma
7.11.1 Octapharma Company Summary
7.11.2 Octapharma Hemophilia Drugs Business Overview
7.11.3 Octapharma Hemophilia Drugs Major Product Offerings
7.11.4 Octapharma Hemophilia Drugs Sales and Revenue in Global (2018-2023)
7.11.5 Octapharma Key News & Latest Developments
7.12 Sangamo Biosciences
7.12.1 Sangamo Biosciences Company Summary
7.12.2 Sangamo Biosciences Hemophilia Drugs Business Overview
7.12.3 Sangamo Biosciences Hemophilia Drugs Major Product Offerings
7.12.4 Sangamo Biosciences Hemophilia Drugs Sales and Revenue in Global (2018-2023)
7.12.5 Sangamo Biosciences Key News & Latest Developments
7.13 Spark Therapeutics
7.13.1 Spark Therapeutics Company Summary
7.13.2 Spark Therapeutics Hemophilia Drugs Business Overview
7.13.3 Spark Therapeutics Hemophilia Drugs Major Product Offerings
7.13.4 Spark Therapeutics Hemophilia Drugs Sales and Revenue in Global (2018-2023)
7.13.5 Spark Therapeutics Key News & Latest Developments
7.14 Swedish Orphan Biovitrum
7.14.1 Swedish Orphan Biovitrum Company Summary
7.14.2 Swedish Orphan Biovitrum Business Overview
7.14.3 Swedish Orphan Biovitrum Hemophilia Drugs Major Product Offerings
7.14.4 Swedish Orphan Biovitrum Hemophilia Drugs Sales and Revenue in Global (2018-2023)
7.14.5 Swedish Orphan Biovitrum Key News & Latest Developments
8 Global Hemophilia Drugs Production Capacity, Analysis
8.1 Global Hemophilia Drugs Production Capacity, 2018-2029
8.2 Hemophilia Drugs Production Capacity of Key Manufacturers in Global Market
8.3 Global Hemophilia Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Hemophilia Drugs Supply Chain Analysis
10.1 Hemophilia Drugs Industry Value Chain
10.2 Hemophilia Drugs Upstream Market
10.3 Hemophilia Drugs Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Hemophilia Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Key Players of Hemophilia Drugs in Global Market
Table 2. Top Hemophilia Drugs Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Hemophilia Drugs Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Hemophilia Drugs Revenue Share by Companies, 2018-2023
Table 5. Global Hemophilia Drugs Sales by Companies, (K Units), 2018-2023
Table 6. Global Hemophilia Drugs Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Hemophilia Drugs Price (2018-2023) & (USD/Unit)
Table 8. Global Manufacturers Hemophilia Drugs Product Type
Table 9. List of Global Tier 1 Hemophilia Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Hemophilia Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Hemophilia Drugs Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Hemophilia Drugs Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Hemophilia Drugs Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Hemophilia Drugs Sales (K Units), 2018-2023
Table 15. By Type - Global Hemophilia Drugs Sales (K Units), 2024-2029
Table 16. By Application ? Global Hemophilia Drugs Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Hemophilia Drugs Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Hemophilia Drugs Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Hemophilia Drugs Sales (K Units), 2018-2023
Table 20. By Application - Global Hemophilia Drugs Sales (K Units), 2024-2029
Table 21. By Region ? Global Hemophilia Drugs Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Hemophilia Drugs Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Hemophilia Drugs Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Hemophilia Drugs Sales (K Units), 2018-2023
Table 25. By Region - Global Hemophilia Drugs Sales (K Units), 2024-2029
Table 26. By Country - North America Hemophilia Drugs Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Hemophilia Drugs Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Hemophilia Drugs Sales, (K Units), 2018-2023
Table 29. By Country - North America Hemophilia Drugs Sales, (K Units), 2024-2029
Table 30. By Country - Europe Hemophilia Drugs Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Hemophilia Drugs Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Hemophilia Drugs Sales, (K Units), 2018-2023
Table 33. By Country - Europe Hemophilia Drugs Sales, (K Units), 2024-2029
Table 34. By Region - Asia Hemophilia Drugs Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Hemophilia Drugs Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Hemophilia Drugs Sales, (K Units), 2018-2023
Table 37. By Region - Asia Hemophilia Drugs Sales, (K Units), 2024-2029
Table 38. By Country - South America Hemophilia Drugs Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Hemophilia Drugs Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Hemophilia Drugs Sales, (K Units), 2018-2023
Table 41. By Country - South America Hemophilia Drugs Sales, (K Units), 2024-2029
Table 42. By Country - Middle East & Africa Hemophilia Drugs Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Hemophilia Drugs Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Hemophilia Drugs Sales, (K Units), 2018-2023
Table 45. By Country - Middle East & Africa Hemophilia Drugs Sales, (K Units), 2024-2029
Table 46. Baxalta Company Summary
Table 47. Baxalta Hemophilia Drugs Product Offerings
Table 48. Baxalta Hemophilia Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 49. Baxalta Key News & Latest Developments
Table 50. Bayer Company Summary
Table 51. Bayer Hemophilia Drugs Product Offerings
Table 52. Bayer Hemophilia Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 53. Bayer Key News & Latest Developments
Table 54. CSL Behring Company Summary
Table 55. CSL Behring Hemophilia Drugs Product Offerings
Table 56. CSL Behring Hemophilia Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 57. CSL Behring Key News & Latest Developments
Table 58. Pfizer Company Summary
Table 59. Pfizer Hemophilia Drugs Product Offerings
Table 60. Pfizer Hemophilia Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 61. Pfizer Key News & Latest Developments
Table 62. Alnylam Pharmaceuticals Company Summary
Table 63. Alnylam Pharmaceuticals Hemophilia Drugs Product Offerings
Table 64. Alnylam Pharmaceuticals Hemophilia Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 65. Alnylam Pharmaceuticals Key News & Latest Developments
Table 66. BioMarin Company Summary
Table 67. BioMarin Hemophilia Drugs Product Offerings
Table 68. BioMarin Hemophilia Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 69. BioMarin Key News & Latest Developments
Table 70. Catalyst Biosciences Company Summary
Table 71. Catalyst Biosciences Hemophilia Drugs Product Offerings
Table 72. Catalyst Biosciences Hemophilia Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 73. Catalyst Biosciences Key News & Latest Developments
Table 74. Dimension Therapeutics Company Summary
Table 75. Dimension Therapeutics Hemophilia Drugs Product Offerings
Table 76. Dimension Therapeutics Hemophilia Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 77. Dimension Therapeutics Key News & Latest Developments
Table 78. F. Hoffmann-La Roche Company Summary
Table 79. F. Hoffmann-La Roche Hemophilia Drugs Product Offerings
Table 80. F. Hoffmann-La Roche Hemophilia Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 81. F. Hoffmann-La Roche Key News & Latest Developments
Table 82. Grifols Company Summary
Table 83. Grifols Hemophilia Drugs Product Offerings
Table 84. Grifols Hemophilia Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 85. Grifols Key News & Latest Developments
Table 86. Octapharma Company Summary
Table 87. Octapharma Hemophilia Drugs Product Offerings
Table 88. Octapharma Hemophilia Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 89. Octapharma Key News & Latest Developments
Table 90. Sangamo Biosciences Company Summary
Table 91. Sangamo Biosciences Hemophilia Drugs Product Offerings
Table 92. Sangamo Biosciences Hemophilia Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 93. Sangamo Biosciences Key News & Latest Developments
Table 94. Spark Therapeutics Company Summary
Table 95. Spark Therapeutics Hemophilia Drugs Product Offerings
Table 96. Spark Therapeutics Hemophilia Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 97. Spark Therapeutics Key News & Latest Developments
Table 98. Swedish Orphan Biovitrum Company Summary
Table 99. Swedish Orphan Biovitrum Hemophilia Drugs Product Offerings
Table 100. Swedish Orphan Biovitrum Hemophilia Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 101. Swedish Orphan Biovitrum Key News & Latest Developments
Table 102. Hemophilia Drugs Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2023 (K Units)
Table 103. Global Hemophilia Drugs Capacity Market Share of Key Manufacturers, 2021-2023
Table 104. Global Hemophilia Drugs Production by Region, 2018-2023 (K Units)
Table 105. Global Hemophilia Drugs Production by Region, 2024-2029 (K Units)
Table 106. Hemophilia Drugs Market Opportunities & Trends in Global Market
Table 107. Hemophilia Drugs Market Drivers in Global Market
Table 108. Hemophilia Drugs Market Restraints in Global Market
Table 109. Hemophilia Drugs Raw Materials
Table 110. Hemophilia Drugs Raw Materials Suppliers in Global Market
Table 111. Typical Hemophilia Drugs Downstream
Table 112. Hemophilia Drugs Downstream Clients in Global Market
Table 113. Hemophilia Drugs Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Hemophilia Drugs Segment by Type in 2022
Figure 2. Hemophilia Drugs Segment by Application in 2022
Figure 3. Global Hemophilia Drugs Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Hemophilia Drugs Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Hemophilia Drugs Revenue, 2018-2029 (US$, Mn)
Figure 7. Hemophilia Drugs Sales in Global Market: 2018-2029 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Hemophilia Drugs Revenue in 2022
Figure 9. By Type - Global Hemophilia Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Hemophilia Drugs Revenue Market Share, 2018-2029
Figure 11. By Type - Global Hemophilia Drugs Sales Market Share, 2018-2029
Figure 12. By Type - Global Hemophilia Drugs Price (USD/Unit), 2018-2029
Figure 13. By Application - Global Hemophilia Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Hemophilia Drugs Revenue Market Share, 2018-2029
Figure 15. By Application - Global Hemophilia Drugs Sales Market Share, 2018-2029
Figure 16. By Application - Global Hemophilia Drugs Price (USD/Unit), 2018-2029
Figure 17. By Region - Global Hemophilia Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Hemophilia Drugs Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Hemophilia Drugs Revenue Market Share, 2018-2029
Figure 20. By Region - Global Hemophilia Drugs Sales Market Share, 2018-2029
Figure 21. By Country - North America Hemophilia Drugs Revenue Market Share, 2018-2029
Figure 22. By Country - North America Hemophilia Drugs Sales Market Share, 2018-2029
Figure 23. US Hemophilia Drugs Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Hemophilia Drugs Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Hemophilia Drugs Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Hemophilia Drugs Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Hemophilia Drugs Sales Market Share, 2018-2029
Figure 28. Germany Hemophilia Drugs Revenue, (US$, Mn), 2018-2029
Figure 29. France Hemophilia Drugs Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Hemophilia Drugs Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Hemophilia Drugs Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Hemophilia Drugs Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Hemophilia Drugs Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Hemophilia Drugs Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Hemophilia Drugs Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Hemophilia Drugs Sales Market Share, 2018-2029
Figure 37. China Hemophilia Drugs Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Hemophilia Drugs Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Hemophilia Drugs Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Hemophilia Drugs Revenue, (US$, Mn), 2018-2029
Figure 41. India Hemophilia Drugs Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Hemophilia Drugs Revenue Market Share, 2018-2029
Figure 43. By Country - South America Hemophilia Drugs Sales Market Share, 2018-2029
Figure 44. Brazil Hemophilia Drugs Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Hemophilia Drugs Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Hemophilia Drugs Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Hemophilia Drugs Sales Market Share, 2018-2029
Figure 48. Turkey Hemophilia Drugs Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Hemophilia Drugs Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Hemophilia Drugs Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Hemophilia Drugs Revenue, (US$, Mn), 2018-2029
Figure 52. Global Hemophilia Drugs Production Capacity (K Units), 2018-2029
Figure 53. The Percentage of Production Hemophilia Drugs by Region, 2022 VS 2029
Figure 54. Hemophilia Drugs Industry Value Chain
Figure 55. Marketing Channels
